Cover Image
市場調查報告書

骨髓炎治療藥:開發中產品分析

Osteomyelitis - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 474976
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
骨髓炎治療藥:開發中產品分析 Osteomyelitis - Pipeline Review, H1 2018
出版日期: 2018年02月20日 內容資訊: 英文 46 Pages
簡介

本報告提供骨髓炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

骨髓炎 - 概要

骨髓炎 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 企業開發中的產品

骨髓炎 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

骨髓炎的治療藥開發企業

骨髓炎 - 藥物簡介

骨髓炎 - 暫停中的計劃

骨髓炎 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10170IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteomyelitis - Pipeline Review, H1 2018, provides an overview of the Osteomyelitis (Infectious Disease) pipeline landscape.

Osteomyelitis is an infection in a bone. Infections can reach a bone by traveling through the bloodstream or spreading from nearby tissue. Symptoms include fever, pain in the area of the infection, swelling, warmth and redness over the area of the infection and irritability. Risk factors bone fracture, sickle cell disease, chemotherapy, diabetes and peripheral arterial disease. Treatment includes surgery and oral antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteomyelitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Osteomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 3 respectively.

Osteomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteomyelitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Osteomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteomyelitis (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteomyelitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Osteomyelitis - Overview
    • Osteomyelitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Osteomyelitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Osteomyelitis - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Debiopharm International SA
    • Motif Bio Plc
    • Nabriva Therapeutics plc
  • Osteomyelitis - Drug Profiles
    • afabicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalbavancin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Osteomyelitis and Bone Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lefamulin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTF-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Osteomyelitis - Dormant Projects
  • Osteomyelitis - Product Development Milestones
    • Featured News & Press Releases
      • Oct 24, 2016: Allergan to Present New Data on DALVANCE (dalbavancin) at IDWeek 2016 in New Orleans
      • Apr 08, 2016: Debiopharm International to present the latest findings on Debio 1450 at ECCMID
      • Oct 10, 2014: Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Osteomyelitis, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Osteomyelitis - Pipeline by Allergan Plc, H1 2018
  • Osteomyelitis - Pipeline by Debiopharm International SA, H1 2018
  • Osteomyelitis - Pipeline by Motif Bio Plc, H1 2018
  • Osteomyelitis - Pipeline by Nabriva Therapeutics plc, H1 2018
  • Osteomyelitis - Dormant Projects, H1 2018

List of Figures

  • Number of Products under Development for Osteomyelitis, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Targets, H1 2018
  • Number of Products by Stage and Targets, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top